When is a diagnostic whole-body radioactive iodine scan indicated after total or near-total thyroidectomy in papillary thyroid carcinoma patients?

When to Perform Whole-Body Radioiodine Scan in Papillary Thyroid Carcinoma

A post-therapy whole-body scan (WBS) should be performed immediately after radioactive iodine (RAI) ablation in all patients who receive RAI therapy, while diagnostic pre-therapy WBS is reserved for intermediate- and high-risk patients to guide treatment decisions—low-risk patients without suspicion for recurrence and with normal neck ultrasound do not require diagnostic WBS. 1

Post-Therapy Scanning: The Standard Approach

Mandatory Post-RAI Therapy Scan

• A post-therapy WBS must be performed after RAI ablation using the radioactivity from the therapeutic dose, as it upstages disease in 6-13% of cases by detecting previously unknown metastases 1
• This scan provides superior sensitivity compared to diagnostic scans due to the higher administered activity 1
• The post-therapy scan serves to evaluate for residual disease and guides subsequent surveillance strategy 1

Diagnostic Pre-Therapy Scanning: Risk-Stratified Approach

Low-Risk Patients: WBS NOT Indicated

• Diagnostic WBS has no role in low-risk patients who have undergone lobectomy 1
• WBS is not utilized in low-risk patients without suspicion for recurrence and with normal thyroid ultrasound 1
• Low-risk criteria include: intrathyroidal tumor ≤1 cm, no extrathyroidal extension, no lymph node metastases, and favorable histology 2

Intermediate- and High-Risk Patients: Consider Diagnostic WBS

• Diagnostic WBS plays a role in evaluating initial response to radioiodine ablation in intermediate- and high-risk patients 1
• Pre-therapy diagnostic scanning combined with stimulated thyroglobulin <1 ng/mL can identify patients who may safely defer RAI therapy, as this combination has only a 2.7% false-negative rate for metastases 3
• When combined with SPECT-CT, diagnostic WBS detects RAI-avid metastases more frequently, particularly lymph node metastases (13.1% vs 4.2% with planar imaging alone) 3
• Diagnostic WBS findings modify patient management in 8.3% of intermediate-risk cases 3

Surveillance Scanning During Follow-Up

Excellent Response to Therapy

• If there has been excellent response to therapy (undetectable thyroglobulin, negative neck ultrasound), WBS is usually not performed for ongoing surveillance 1
• Periodic WBS may not be necessary in low-risk patients who have had remnant ablation, normal initial ultrasound, and low serum thyroglobulin 1

Suspected Recurrence or Persistent Disease

• In intermediate- and high-risk patients with detectable thyroglobulin, distant metastases, or soft tissue invasion, radioiodine imaging should be performed every 12 months until no response is seen to RAI treatment in iodine-responsive tumors 1
• Uptake scanning in the thyroid bed can aid in detection of local recurrence and guide therapy 1
• Either I-123 or I-131 can be used for diagnostic scanning, though I-123 provides better image quality 1

Thyroglobulin-Guided Decision Making

When to Consider Diagnostic WBS Based on Thyroglobulin

• If stimulated thyroglobulin is 1-10 ng/mL with negative imaging, consider radioiodine therapy with 100-150 mCi followed by post-treatment imaging 1
• If stimulated thyroglobulin is >10 ng/mL, strongly consider radioiodine therapy with post-treatment imaging 1
• If I-131 imaging is negative and stimulated thyroglobulin is >2-5 ng/mL, consider non-radioiodine imaging such as FDG-PET/CT (particularly if thyroglobulin >10 ng/mL) 1

Critical Pitfalls to Avoid

Common Errors in WBS Utilization

• Do not perform routine surveillance WBS in low-risk patients with excellent response to therapy—this leads to unnecessary radiation exposure without clinical benefit 1
• Do not rely solely on diagnostic WBS without post-therapy scanning in patients receiving RAI, as post-therapy scans detect additional disease in a significant proportion of cases 1
• Do not use FDG-PET/CT for routine surveillance if there is no residual disease—reserve this modality for patients with elevated thyroglobulin and negative radioiodine scans 1
• Recognize that stunning (reduced RAI uptake after diagnostic scanning) is rarely observed and does not impair proper treatment of metastases 3

Special Considerations for Intermediate-Risk Patients

• In selected intermediate-risk patients (particularly those with N1 disease), obtain stimulated thyroglobulin and consider concomitant diagnostic RAI imaging to determine whether RAI treatment is indicated 1
• RAI is often beneficial in iodine-avid disease but not in non-iodine-avid disease, making pre-therapy diagnostic scanning valuable for treatment planning 1
• A pre-therapy stimulated thyroglobulin <1 ng/mL combined with negative diagnostic WBS is highly suggestive of absence of remaining malignant disease, and one may consider deferring RAI ablation if both are negative 3